EBS - Emergent BioSolutions Inc.
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Gaithersburg,
United States
Type: Equity
EBS price evolution
EBS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $71 | $79 | $111.7 | |
| Short term investments | ||||
| Net receivables | $121.3 | $196.3 | $233.5 | $191 |
| Inventory | $322.7 | $317.5 | $333.4 | $328.9 |
| Total current assets | $661.4 | $654.5 | $682.4 | $679.5 |
| Long term investments | ||||
| Property, plant & equipment | $290.5 | $306.2 | $379.4 | $382.8 |
| Goodwill & intangible assets | $534.1 | $550.4 | $566.6 | |
| Total noncurrent assets | $859 | $1121.2 | $1143.7 | |
| Total investments | ||||
| Total assets | $1477.8 | $1513.5 | $1803.6 | $1823.2 |
| Current liabilities | ||||
| Accounts payable | $82.1 | $95.9 | $100.2 | $112.2 |
| Deferred revenue | ||||
| Short long term debt | $415.2 | $459.2 | $413.7 | |
| Total current liabilities | $229.9 | $619.7 | $630.2 | $651.3 |
| Long term debt | $661.8 | $447 | $446.7 | $446.5 |
| Total noncurrent liabilities | $507.5 | $509.5 | $522.6 | |
| Total debt | $862.2 | $905.9 | $860.2 | |
| Total liabilities | $969.4 | $1127.2 | $1139.7 | $1173.9 |
| Shareholders' equity | ||||
| Retained earnings | -$181.1 | -$295.9 | -$12.8 | -$21.8 |
| Other shareholder equity | -$7.3 | -$5.5 | -$5.5 | -$5.7 |
| Total shareholder equity | $386.3 | $663.9 | $649.3 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $111.7 | $642.6 | $576.3 | $621.5 |
| Short term investments | ||||
| Net receivables | $191 | $158.4 | $274.7 | $230.9 |
| Inventory | $328.9 | $351.8 | $350.8 | $307 |
| Total current assets | $679.5 | $1210.7 | $1272.1 | $1195.9 |
| Long term investments | ||||
| Property, plant & equipment | $382.8 | $837 | $800.1 | $644.1 |
| Goodwill & intangible assets | $566.6 | $947 | $829.5 | $929.8 |
| Total noncurrent assets | $1143.7 | $1955.9 | $1686.9 | $1687.3 |
| Total investments | ||||
| Total assets | $1823.2 | $3166.6 | $2959 | $2883.2 |
| Current liabilities | ||||
| Accounts payable | $112.2 | $103.5 | $128.9 | $136.1 |
| Deferred revenue | ||||
| Short long term debt | $413.7 | $957.3 | $31.6 | $33.8 |
| Total current liabilities | $651.3 | $1229.9 | $373.8 | $384.5 |
| Long term debt | $446.5 | $448.5 | $809.4 | $841 |
| Total noncurrent liabilities | $522.6 | $553.7 | $966.2 | $1051.7 |
| Total debt | $860.2 | $1405.8 | $841 | $874.8 |
| Total liabilities | $1173.9 | $1783.6 | $1340 | $1436.2 |
| Shareholders' equity | ||||
| Retained earnings | -$21.8 | $734 | $957.8 | $726.9 |
| Other shareholder equity | -$5.7 | $3.1 | -$16.1 | -$25.3 |
| Total shareholder equity | $649.3 | $1383 | $1619 | $1447 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $254.7 | $300.4 | $276.6 | |
| Cost of revenue | $296.1 | $144.6 | $185.1 | |
| Gross Profit | -$41.4 | $155.8 | $91.5 | |
| Operating activities | ||||
| Research & development | $32.7 | $15.1 | $29.4 | |
| Selling, general & administrative | $85.9 | $84.7 | $89.7 | |
| Total operating expenses | $162.1 | $116 | $135.3 | |
| Operating income | -$203.5 | $39.8 | -$43.8 | |
| Income from continuing operations | ||||
| EBIT | -$246.2 | $36.4 | -$32.8 | |
| Income tax expense | $13.3 | $3.1 | -$5 | |
| Interest expense | $23.6 | $24.3 | $21.7 | |
| Net income | ||||
| Net income | -$283.1 | $9 | -$49.5 | |
| Income (for common shares) | -$283.1 | $9 | -$49.5 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1049.3 | $1120.9 | $1792.7 | $1555.4 |
| Cost of revenue | $705.4 | $693.7 | $757.5 | $524 |
| Gross Profit | $343.9 | $427.2 | $1035.2 | $1031.4 |
| Operating activities | ||||
| Research & development | $111.4 | $193 | $234 | $234.5 |
| Selling, general & administrative | $368.4 | $340.3 | $348.4 | $303.3 |
| Total operating expenses | $1070.3 | $599.9 | $682.6 | $597.6 |
| Operating income | -$726.4 | -$172.7 | $352.6 | $433.8 |
| Income from continuing operations | ||||
| EBIT | -$643.3 | -$184.4 | $348.9 | $438.5 |
| Income tax expense | $29.3 | $2.1 | $83.5 | $102.1 |
| Interest expense | $87.9 | $37.3 | $34.5 | $31.3 |
| Net income | ||||
| Net income | -$760.5 | -$223.8 | $230.9 | $305.1 |
| Income (for common shares) | -$760.5 | -$223.8 | $230.9 | $305.1 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$283.1 | $9 | -$49.5 | |
| Operating activities | ||||
| Depreciation | $28.5 | $27.9 | $29.6 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.5 | $5.9 | $4 | |
| Total cash flows from operations | $47.5 | -$62.6 | $32.1 | |
| Investing activities | ||||
| Capital expenditures | -$4.6 | -$10.8 | -$11.4 | |
| Investments | ||||
| Total cash flows from investing | $96.6 | -$4.6 | -$10.8 | -$11.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.7 | $0.7 | ||
| Net borrowings | -$51.4 | $41.1 | $4.1 | |
| Total cash flows from financing | -$190.5 | -$50.9 | $40.7 | $4.7 |
| Effect of exchange rate | -$1.5 | |||
| Change in cash and equivalents | $44.7 | -$8 | -$32.7 | $23.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$760.5 | -$223.8 | $230.9 | $305.1 |
| Operating activities | ||||
| Depreciation | $125.1 | $143.3 | $123.8 | $114.5 |
| Business acquisitions & disposals | $263.9 | -$243.7 | -$10 | |
| Stock-based compensation | $23.1 | $45.1 | $42.4 | $51 |
| Total cash flows from operations | -$206.3 | -$34.1 | $321.1 | $536 |
| Investing activities | ||||
| Capital expenditures | -$51.6 | -$115.8 | -$225 | -$141 |
| Investments | ||||
| Total cash flows from investing | $212.3 | -$381.3 | -$225 | -$151 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $10.2 | -$77.1 | -$90.1 | $31.6 |
| Net borrowings | -$543.4 | $564.2 | -$35.9 | $54.5 |
| Total cash flows from financing | -$535.7 | $481.2 | -$141 | $69.5 |
| Effect of exchange rate | -$1.2 | $0.5 | -$0.3 | -$1 |
| Change in cash and equivalents | -$530.9 | $66.3 | -$45.2 | $453.5 |
News
Fundamentals
| Market cap | $594.56M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 54.10M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.81 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.88 |
| Quick ratio | 1.47 |